Recent progress in analyzing the structures and functions of G-protein coupled receptors (GPCRs) including > -adrenoceptors (>-ARs) has been made by pharmacological, physiological and molecular biological techniques. The three-dimensional (3D) structures, interaction sites with ligands and conformational changes of these receptor subtypes due to ligand binding are now better understood by the simulation of these receptors using computer-aided molecular modeling. Based on these techniques, numbers and conformations of amino acid sequences of each subtype (> 1-, >2and >3-ARs) were defined and also interaction sites or modes of interaction between ligands and >-ARs could be analyzed three-dimensionally. In addition, simulation of 3D structures of > -ARs by molecular modeling could clearly determine the limited size, space or pocket for fitting with ligands. These studies will give some clues for the clarification of other GPCRs. Thus, this review summarizes current findings on chemical structures of ligands, amino acid sequences, 3D structures and important amino acids of >-AR subtypes for interacting with ligands obtained from mutagenesis, chimeric studies and molecular modeling techniques.
Introduction
The > -adrenoceptors (>-AR) belong to a large family of G-protein-coupled receptors GPCRs that are characterized by seven transmembrane helices. Three subtypes of >-ARs (> 1, > 2 and >3) have been characterized by pharmacological, biochemical and molecular biological cloning approaches (1), while Kaumann et al. reported the existence of > 4-ARs in the mammalian heart (2) . Granneman used the >3-AR agonist CGP 12177 to define a novel atypical >-AR subtype, the putative > 4-AR (3) . In addition, molecular modeling techniques are also giving us much information on chemical interactions between ligands and receptors. Thus, tremendous and epochal studies using these multiple approaches will contribute to elucidating the structures and functions of > -ARs. As > -AR ligands (agonists and antagonists) are clinically becoming very important for treating many kinds of diseases (4 -7) , this review will focus on the structure of > -adrenoceptors and their ligands, their interaction sites as well as transduction of signals from the receptors to the G proteins.
Structure and structure-activity relationship of ,-AR ligands
The first trial to clarify the structure-function relationship of >-AR ligands was done by Lands et al. (8) . The basic structures of > -AR ligands are 1) phenylethanolamine and 2) phenoxypropanolamine. The compounds of phenylethanolamine series are consisting of a benzene ring and an ethylamine side chain which contains a hydroxyl group at the > -carbon. Most of these compounds (epinephrine, isoproterenol, BRL 37344, etc.) exhibit agonistic properties towards >1/> 2/ >3-AR. On the other hand, the compounds of phenoxypropanolamine series are consisting of a phenoxy group attached to a >-hydroxypropanolamine side chain. All of these compounds show antagonism towards >1and >2-AR, but they are agonists of > 3-AR, and only few (ICI 118551, CGP 20712A, bupranolol, etc.) exhibit >3-AR antagonistic activity. There are, however, a few exceptions and those compounds are dichloroisoprenaline, pronethalol, sotalol, etc., which possess the ethanolamine side chain, but show antagonistic activity towards >1and >2-AR. Thus, the important conformation involved in >2-AR activity consisted of the dimensional chemical arrangement of catechol OH, OH in the beta position, and N-H binding (9) .
In recent years, as mentioned above, agonists (BRL 37344A, BRL 35135A) with strong selectivity for >3-ARs have been reported (10) . Blin et al. reported structural characteristics of the three pharmacological classes of >-ARs. The selective or potent >3-AR ligands show common structural characteristics, i.e., 18 -20-carbon backbone length, a substituted or unsubstituted aromatic ring, and an (oxy)hydroxylalkylamine chain ending in an indol function or a phenyl carrying hydroxyl, ether or acid functions, which increase steric bulk and moderate lipophilicity (10) . These conformational characteristics of these subtype ligands are almost the same as those of > 1-and >2-ARs, but only differences in these subtypes are the aromatic ring and bulky and long substituents of amino side chains. However, there are three types of agonists and antagonists for > 3-ARs. Those are 1) the potent > 1 />2/ > 3-AR agonists (BRL 37344, LY 79771), 2) >3-agonist, > 1/ > 2-antagonists (alprenolol, oxprenolol) and 3) >1/> 2/ > 3-antagonists (bupranolol, CGP 20712A, ICI 118551). In addition, >3-AR agonists also show two kinds of chemical structures: 1) phenylethanolamine (BRL 37344, LY 79771) and 2) phenoxypropanolamine (bucindolol, ICI 201651) series. These compounds have different length with respect to the number of carbons. Therefore, in 1993, Blin et al. suggested that several compounds can adopt either folded or extended conformations for best fit into their respective receptor surface for interactions, and these authors used molecular dynamics modeling to analyze the three-dimensional (3D) structures of compounds. They also suggested that the folded conformations of pindolol, cyanopindolol and CGP 12177A are in large part responsible for their >1/ >2antagonists activity, whereas extended conformations of these compounds are responsible for the > 3-agonist activity (10) . Recently, Konkar et al. reported the anomalous biphasic effects of CGP 12177 on > 1-AR. Low concentrations of CGP 12177A potently blocked isoproterenol-induced stimulation of > 1-AR, whereas high concentration of this compound stimulated the > 1-AR (11) .
Thus, ligand conformation plays an important role in the efficacy of ligands to interact with different receptor subtypes for agonistic or antagonistic activity. The addition of a hydrophobic group to the amino end of the > -AR ligand pharmacophore can result in molecules that are capable of existing in either extended or folded conformation in space. For small molecules, transconformation is mainly due to rotation around the C =-C> bond of the hydroxyethyl amine chain but for large molecules, rotation occurs around both C=-C> and C='-C>' bonds of the hydroxyethyl amine chain.
The 3D interatomic distances between the reacting atoms in a ligand are important for eliciting pharmacological effects (10) . In different conformational adoption (extended and folded) of molecules, this distance between involved atoms will vary. Thus, a particular conformation of a ligand will induce pharmacological effects at a particular receptor subtype, and this will resemble other ligands at the 3D level. Figure 1 shows the schematic representation of the >3-AR minimal pharmacophore in postulated extended and folded conformation. Interatomic distances vary markedly in different conformations, as can be assumed from the figure. 
Structure of , -AR subtypes
>-ARs are one of the GPCRs. Kobilka et al. were able to determine the entire structure of a > 2-AR, which is now known to be composed of 413 amino acids; and the structure of a human > 1-and > 3-AR have also been determined, each being composed of 477 and 408 amino acids, respectively (12) . The human >3-AR was shown to have 49% and 51% overall homology at the amino acid sequence to human >2-AR and >1-AR, respectively (13, 14) .
Important interaction sites between ligands and ,-AR subtypes Mutagenesis studies
Deletion mutagenesis of the >2-AR revealed that the ligand binding domain for small AR agonists and antagonists resides within the conserved hydrophobic core of the receptor (15) . As mentioned above, it is considered that there are several functional groups in their structures for interactions with >-ARs (Table 1) .
1) The metaand para-hydroxyl groups: these groups form hydrogen bonds with Ser 204 and Ser 207 , respectively, on TM5 of >2-AR (16) . If agonist interaction with the receptor involves the formation of specific hydrogen bonds with serine residues on TM5, then the binding might cause conformational changes in this helix that could be transmitted to the residues at the bottom of the helix, catalyzing the interaction of this region with Gs. Antagonists that do not appear to interact with Ser 204 and Ser 207 would not be expected to promote this conformational change.
2) beta-Hydroxyl group: the hydroxyl group of the ethanolamine side-chain interacts with Ser 161 on TM4 of >2-AR by a hydrogen bond (17) . However, a hydrogen bond is also formed when > 3-AR agonist interacts with Ser 169 on TM7 of >3-AR (1).
3) Charged amine group: this charged amine interacts with the carboxylated side chain of Asp 113 on TM3 of >2-AR (18, 19) . Structure-activity analysis of AR ligands has shown the amine moiety of both agonists and antagonists to be essential for the interaction with the >-ARs (20, 21) . Strader et al. reported that substitution of Asp 113 with a glutamic acid residue resulted in a mutant >-AR that recognizes several known >-AR antagonists (alprenolol, Table 1 . Ligand binding sites on > 2-and > 3-AR pindolol, propranolol) as partial agonists. These results suggest the existence of overlapping binding sites for agonists and antagonists on the >-ARs (22) . 4) Aromatic catechol ring: this aromatic ring can interact Phe 289 and Phe 290 in TM6 (23) . Thus, these catechol ring and hydroxyl group interactions would serve to specifically orient the catechol ring of the agonist in the binding site of the receptor (24) . Several findings reveal that the aryloxy end of antagonist interacts with TM6 and TM7. Suryanarayana and Kobilka proposed that Asn 312 in TM7 forms a hydrogen bond with the aryloxy oxygen of the antagonist pharmacophore (25) .
On the other hand, a > 3-AR agonist (BRL 37344) differs significantly from the other subtype agonists in terms of pharmacology and this recognized several > 3-AR compounds acting as potent > 1-and >2-AR antagonists. The amino acids that were involved in the binding of the ligands were also identified by site-directed mutagenesis and photoaffinity labeling of the > 3-ARs. As shown in Table 1 , those were Asp 117 in TM3 (hydrogen bond with amine), Ser 169 in TM4 (hydrogen bond with the hydroxyl group of the ethanolamine side-chain), Ser 209 and Ser 212 in TM5 (hydrogen bond with the hydroxyl groups of the catechol side chain) and Phe 309 in TM5 (hydrophobic interaction with the aromatic ring of the catecholamine), respectively (1, 26, 27) . The interactive amino acids of >-AR subtypes with the functional groups of the ligands are shown in Fig. 2 .
Chimeric studies
The TM4 was largely responsible for determining >1vs > 2-AR properties with respect to agonist binding by using chimeric >1/ >2-AR gene expression. TM6 and TM7 play an important role in determining binding of > 1-and >2-selective antagonists (28). Isogaya et al. also suggested that the major amino acid of >2-AR interacting with the >2-selective binding of salmeterol (>2-AR agonist) was Tyr 308 in TM7 and that the position of the ether oxygen in the side chain was also important for > 2-selective binding (29) .
Photoaffinity label studies
The interactions between > -AR antagonists and the >2-AR were studied with the use of photoaffinity labels (30) . These authors indicated that the aryloxy end of the > 2-AR antagonist pharmacophore is highly constrained within TM6 and TM7 by using the 125 I-iodocyanopindololdiazarene (ICYPdz), whereas the amino terminus is much less constrained and able to assume multiple conformations. These photoaffinity labeling studies data were in agreement with the results of the mutagenesis data, which suggest the involvement of regions within TM2 and TM7 in antagonist binding to the >-AR (31, 32) .
Fluorescence probe analysis
Tota and Strader showed that the antagonist binds to the >-AR in a rigid hydrophobic environment which is buried deep within the core of the protein by the method of carazolol (a high affinity >-AR antagonist) fluorescence probe analysis (33) . 
Analysis of binding sites in > > > >-AR subtypes by molecular modeling
Molecular modeling technique is useful for analyzing the 3D structures of compounds at >-AR subtypes because the >-AR ligands exist in either a folded or extended conformation in the pockets of > -ARs. This molecular dynamics simulation could predict that 125 I-iodoazidothiophenylalprenolol (IABP), 125 I-iodoazidophenyl CGP 12177A (IAPCGP) and ICYPdz favor a folded conformation, with both ends close together (30) . These authors also indicated that derivatization of TM6 and TM7 by these photolabelled compounds suggests the folded conformation of these compounds in the ligand binding pocket. On the other hand, our laboratory deduced 3D structures of human >-ARs and profiles of >-AR antagonists binding by computer simulation based on the electron density map of rhodopsin (34, 35) . This modeling analysis supported the results of molecular biological-/pharmacological-experiments and further gave us some novel interesting suggestions. We assumed that the amine, benzoic acid, indole methyl, t-butyl, phenyl and indole functional groups of bopindolol possibly interact with Asp 138 (TM3), Ser 190 (TM4), Ala 343 (TM6), Val 137 (TM3), Pro 339 (TM6), Cys 336 (TM6), Leu 237 (TM5) and Pro 236 (TM5) of >1-AR, respectively, by either hydrogen bonding or hydrophobic interactions (35) . Thus, the analysis of interaction between ligands and receptors by this computer simulation will give us newer information of highly and more precise 3D structures of >-AR subtypes and/or different interactions in these subtypes.
Conformational changes induced by agonists and antagonists
Binding of ligand is presumed to induce a change in conformation in the receptor, which in case of the agonist is transmitted as a signal for activation of the GS. During agonist binding to > 2-AR, certain conformational changes to the receptor occur. As for example, when catechol compounds bind with the receptor, the Ser 204 and Ser 207 residues of TM5 contribute to ligand binding through its catechol moiety and Ser 165 (36)/ Ser 161 (21) residue of TM4 contributes through its beta-hydroxyl group. Meanwhile, the Tyr 316 side chain of TM7 moves from Asp 113 of TM3 to the Asp 79 residue of TM2 to avoid steric hindrance with the agonist molecule and to favor hydrogen bond interaction. This conformational modification by the agonist molecule could thus initiate signal processing through other polar side chains found near helices 1 -3 and 7 on the cytoplasmic side of the receptor (36) .
On the other hand, during antagonist binding to >2-AR, the change in receptor conformation is slightly different from that occurring in the case of agonist binding. Most >2-AR antagonists are phenoxy propanolamine compounds. The Asp 113 of TM3 participates in a favorable attraction with the cationic amino group and Ser 165 of TM6 (36) or Asn 312 of TM7 (37) , with the ether group of the ligand. Due to the particular position of the antagonist ligand inside the groove, the N-part of this molecule points deeper inside the signal region and pushes the tyrosine side-chain previously bound to the Asp 113 residue on TM3 towards the Asn 312 residue on TM7. In such a position, a hydrogen bond between the phenol hydroxyl and the amino sidechain can be formed, thus preventing the interaction between the Tyr 316 and Asp 79 residue of TM2.
Transduction from binding sites with > > > >-ARs to G protein
The interaction between receptors and G proteins presumably occurs at the inner surface of the plasma membrane of the cell where the G proteins are located. For this reason it was predicted that the internal loops of the receptors should be involved in the activation of G protein (38) . Strader et al. proposed that the agonist-specific hydrogen bonding interactions are localized in the TM5 of >-ARs that suggests a mechanism for agonist activation of the receptor. The interaction of the receptor with G protein has been postulated to involve residues within TM3 of the receptor, which connects the TM5 and TM6. Specifically, the interaction of the >-AR with Gs requires a stretch of residues at the N-terminal portion of this loop, predicted to form a cytoplasmically exposed amphipathic =-helix located at the bottom of the TM5 (39) .
Perspectives of GPCR including >
> > >-AR study However even though GPCRs, especially adrenoceptors, have been investigated from many viewpoints, they are still attractive targets of study with respect to their 3D structures and relationships between their structures and functions. Structural biology will be a very useful approach to describe physiological events from the molecular point of view following the genome project. As a matter of fact, the number of articles about structure-function relationships have multiplied in these recent years. Very recently, the crystal structure of rhodopsin was determined (40) . The members of GPCR are believed to share the same arrangement of the membrane-embedded parts. Therefore, the determination of the rhodopsin structure should be a major breakthrough. However, the loops connecting the helices, especially the intracellular loops, and N-and Cterminals have low homologies with each GPCR and their lengths are varied. The variation in the regions may reflect the specificities of each GPCR. In the near future, the structures of other GPCRs will also be determined, which will give us useful and logical information to describe the relationships of structure-specificity and conformational change-function and the mode of ligand binding. It will advance the developments of therapeutic drugs.
On the other hand, orphan GPCRs have been and also will be found following the genome project. The physiological functions and endogenous ligands of orphan GPCRs are also interesting from pharmacological and therapeutic points of view. Recently, a novel mechanism that modulates GPCR functions has been reported. Oligomerization between GPCRs could change their affinities to ligands and efficacies. In addition, GPCR and other types of hormonal receptors also could form a heterodimer and change their functions (41) . This modulation might reflect pharmacological diversities of GPCRs. Ophan GPCRs and oligomer of GPCRs point to additional targets for the development of therapeutic drugs.
Determination of rhodopsin structure will greatly advance structural biological analyses of GPCRs. Cooperation between molecular biology and structure biology encourages making dynamic structure-function relationships of GPCRs clear. The relationships would describe the mechanisms of GPCRs as a switch to relay the signal to G proteins and various states of GPCRs binding full, partial and inverse agonists. Furthermore, it would contribute to the discovery of the endogenous ligands, help identify the function of orphan receptors, and elucidate, the modulation of functions by oligomerization.
We now face a new situation of GPCR studies and the study of GPCRs will be more exciting.
